DeBoer Douglas J, Verbrugge Maria, Morris Mary
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, 2015 Linden Drive, Madison, WI, 53706, USA.
Allergy Associates of La Crosse, 2727 Midwest Drive, Onalaska, WI, 54650, USA.
Vet Dermatol. 2016 Apr;27(2):82-7e23. doi: 10.1111/vde.12284. Epub 2016 Jan 8.
Sublingual immunotherapy (SLIT) has been reported to be beneficial in people with atopic dermatitis (AD) and dust mite sensitivity. Evaluation of this therapy has not been reported in spontaneous canine AD.
The objective of this study was to preliminarily evaluate the effectiveness of an established SLIT protocol, as used in human patients, in dogs with AD.
Ten dust mite sensitive dogs with spontaneous AD.
Dogs underwent a 6 month open trial of SLIT concurrently with decreasing dose oral methylprednisolone. Clinical evaluations and quantitative serum anti-mite IgE and IgG levels were performed every 2 months.
Mean methylprednisolone use from the first 2 months of the study to the final 2 months declined from 10.2 to 4.3 mg/kg/2 months (P < 0.001, Student's paired t-test); at 6 months, four dogs required no oral corticosteroid administration. Over the course of the study, median Canine Atopic Dermatitis Extent and Severity Index (CADESI)-03 scores declined from 76.5 to 59; median pruritus scores declined from 65 to 37 (P < 0.02 and P < 0.01, respectively; Wilcoxon signed-rank test). Pre- and post-SLIT intradermal test scores for mite allergen were not significantly different over time. Median Dermatophagoides farinae (DF)-specific IgE levels declined significantly from 150.2 × 10(3) AU/mL to 3.6 × 10(3) AU/mL (P < 0.05). Concurrently, median DF-specific IgG levels increased from 18.5 × 10(6) AU/mL to 3923.4 × 10(6) AU/mL (P < 0.05; Wilcoxon signed-rank tests).
SLIT treatment produced clinical improvement in dogs with dust mite-associated AD and was associated with serological changes supporting this improvement. Further studies in larger numbers of dogs and those with polysensitization are warranted.
据报道，舌下免疫疗法（SLIT）对患有特应性皮炎（AD）且对尘螨敏感的人有益。尚未有关于自发性犬类AD中该疗法评估的报道。
本研究的目的是初步评估用于人类患者的既定SLIT方案对患有AD的犬的有效性。
十只对尘螨敏感的自发性AD犬。
犬在接受SLIT的6个月开放试验的同时，口服甲基强的松龙的剂量逐渐减少。每2个月进行临床评估以及定量检测血清抗螨IgE和IgG水平。
从研究的前2个月到最后2个月，甲基强的松龙的平均用量从10.2毫克/千克/2个月降至4.3毫克/千克/2个月（P<0.001，学生配对t检验）；在6个月时，四只犬无需口服皮质类固醇。在研究过程中，犬特应性皮炎范围和严重程度指数（CADESI）-03评分中位数从76.5降至59；瘙痒评分中位数从65降至37（分别为P<0.02和P<0.01；Wilcoxon符号秩检验）。SLIT前后螨过敏原皮内试验评分随时间无显著差异。粉尘螨（DF）特异性IgE水平中位数从150.2×10³AU/mL显著降至3.6×10³AU/mL（P<0.05）。同时，DF特异性IgG水平中位数从18.5×10⁶AU/mL增至3923.4×10⁶AU/mL（P<0.05；Wilcoxon符号秩检验）。
SLIT治疗使患有尘螨相关AD的犬的临床症状得到改善，并伴有支持这种改善的血清学变化。有必要对更多犬以及多致敏犬进行进一步研究。
